XML 63 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Revenue Recognition (Details)
12 Months Ended
Dec. 31, 2023
USD ($)
agreement
item
Dec. 31, 2022
USD ($)
Disaggregation of Product Revenue    
Number of distribution agreements | agreement 2  
Mytesi    
Disaggregation of Product Revenue    
Product revenue $ 9,600,000 $ 11,700,000
Number of specialty pharmacies. | item 5  
Mytesi | Specialty Pharmacies    
Disaggregation of Product Revenue    
Product revenue $ 8,100,000 10,300,000
Canalevia-CA1    
Disaggregation of Product Revenue    
Product revenue 130,000 167,000
Neonorm    
Disaggregation of Product Revenue    
Product revenue $ 42,000 $ 48,000